Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Highlights

Highlights In This Issue September 2018 Volume 4, Number 9 JAMA Oncology Pages 1145-1308 Research LETTERS Research Letter ERBB Mutations and Targeted Therapies for Lung Cancer 1189 1287 Long-term Results of Stereotactic ERBB gene mutations may affect the efficacy of therapies targeting the ERBB signaling path- Body Radiation Therapy in Medically way. Goss et al evaluated the association between the ERBB family of mutations and out- Inoperable Stage I Non–Small Cell Lung Cancer comes in afatinib- or erlotinib-treated patients with lung squamous cell carcinoma using RD Timmerman and Coauthors samples from the LUX-Lung 8 trial. Of 245 evaluable patients, 53 had tumors with at least 1288 Association of Definitive Pelvic 1ERBBmutation.Amongafatinib-treatedpatients,progression-freeandoverallsurvivalwere Radiation Therapy With Survival longer in those with ERBB mutation–positive disease—in particular HER2 mutations—than Among Patients With Newly in those without. HER2 mutations may be a biomarker for prioritizing afatinib treatment in Diagnosed Metastatic Cervical Cancer this population. Gandara et al provide an Invited Commentary. Y Wang and Coauthors Invited Commentary 1197 1291 Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial Trastuzumab Duration in HER2-Positive Breast Cancer 1199 MM Pasquinelli and Coauthors Joensuu et al report the results of the SOLD trial examining http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Highlights

JAMA Oncology , Volume 4 (9) – Sep 1, 2018
Download PDF
1 page

Highlights

Abstract

In This Issue September 2018 Volume 4, Number 9 JAMA Oncology Pages 1145-1308 Research LETTERS Research Letter ERBB Mutations and Targeted Therapies for Lung Cancer 1189 1287 Long-term Results of Stereotactic ERBB gene mutations may affect the efficacy of therapies targeting the ERBB signaling path- Body Radiation Therapy in Medically way. Goss et al evaluated the association between the ERBB family of mutations and out- Inoperable Stage I Non–Small Cell Lung Cancer comes in afatinib-...
Loading next page...
 
/lp/american-medical-association/highlights-VEjgU0DJRo

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.3245
Publisher site
See Article on Publisher Site

Abstract

In This Issue September 2018 Volume 4, Number 9 JAMA Oncology Pages 1145-1308 Research LETTERS Research Letter ERBB Mutations and Targeted Therapies for Lung Cancer 1189 1287 Long-term Results of Stereotactic ERBB gene mutations may affect the efficacy of therapies targeting the ERBB signaling path- Body Radiation Therapy in Medically way. Goss et al evaluated the association between the ERBB family of mutations and out- Inoperable Stage I Non–Small Cell Lung Cancer comes in afatinib- or erlotinib-treated patients with lung squamous cell carcinoma using RD Timmerman and Coauthors samples from the LUX-Lung 8 trial. Of 245 evaluable patients, 53 had tumors with at least 1288 Association of Definitive Pelvic 1ERBBmutation.Amongafatinib-treatedpatients,progression-freeandoverallsurvivalwere Radiation Therapy With Survival longer in those with ERBB mutation–positive disease—in particular HER2 mutations—than Among Patients With Newly in those without. HER2 mutations may be a biomarker for prioritizing afatinib treatment in Diagnosed Metastatic Cervical Cancer this population. Gandara et al provide an Invited Commentary. Y Wang and Coauthors Invited Commentary 1197 1291 Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial Trastuzumab Duration in HER2-Positive Breast Cancer 1199 MM Pasquinelli and Coauthors Joensuu et al report the results of the SOLD trial examining

Journal

JAMA Oncology – American Medical Association

Published: Sep 1, 2018

There are no references for this article.